Thomas, K.; Voros, B.A.; Meadows-Taylor, M.; Smeltzer, M.P.; Griffin, R.; Boudreaux, J.P.; Thiagarajan, R.; Woltering, E.A.; Ramirez, R.A.
Outcomes of Capecitabine and Temozolomide (CAPTEM) in Advanced Neuroendocrine Neoplasms (NENs). Cancers 2020, 12, 206.
https://doi.org/10.3390/cancers12010206
AMA Style
Thomas K, Voros BA, Meadows-Taylor M, Smeltzer MP, Griffin R, Boudreaux JP, Thiagarajan R, Woltering EA, Ramirez RA.
Outcomes of Capecitabine and Temozolomide (CAPTEM) in Advanced Neuroendocrine Neoplasms (NENs). Cancers. 2020; 12(1):206.
https://doi.org/10.3390/cancers12010206
Chicago/Turabian Style
Thomas, Katharine, Brianne A. Voros, Meghan Meadows-Taylor, Matthew P. Smeltzer, Ryan Griffin, J. Philip Boudreaux, Ramcharan Thiagarajan, Eugene A. Woltering, and Robert A. Ramirez.
2020. "Outcomes of Capecitabine and Temozolomide (CAPTEM) in Advanced Neuroendocrine Neoplasms (NENs)" Cancers 12, no. 1: 206.
https://doi.org/10.3390/cancers12010206
APA Style
Thomas, K., Voros, B. A., Meadows-Taylor, M., Smeltzer, M. P., Griffin, R., Boudreaux, J. P., Thiagarajan, R., Woltering, E. A., & Ramirez, R. A.
(2020). Outcomes of Capecitabine and Temozolomide (CAPTEM) in Advanced Neuroendocrine Neoplasms (NENs). Cancers, 12(1), 206.
https://doi.org/10.3390/cancers12010206